Actively Recruiting
A Novel Strategy of ECMO Management Using Nafamostat for Regional Combined With Low Intensity Systematic Anticoagulation
Led by Beijing Chao Yang Hospital · Updated on 2024-11-18
60
Participants Needed
1
Research Sites
165 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
ECMO is widely used in patients with refractory respiratory and/or circulatory failure.The data shows that the incidence of bleeding and thrombotic events is still above 40%,and it is closely related to the increase in mortality rate.Therefore, optimizing ECMO anticoagulation management to reduce bleeding and thrombotic events is a key scientific issue that urgently needs to be addressed.
CONDITIONS
Official Title
A Novel Strategy of ECMO Management Using Nafamostat for Regional Combined With Low Intensity Systematic Anticoagulation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age older than 18 years old
- Received ECMO because of severe respiratory failure
You will not qualify if you...
- Anticoagulant contraindications
- Cerebral infarction or suspected patients
- Severe hypertension
- Women in gestational and lactational period
- Hemophilia
- Allergic to heparin or Nafamostat
- Unwilling or unable to complete the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Bing Sun
Beijing, Beijing Municipality, China, 100020
Actively Recruiting
Research Team
B
Bing Sun, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here